TickerGuard
Buy Day today: Neutral (54) Mixed market breadth · no major macro event
KRRO

Korro Bio, Inc.

Healthcare · Biotechnology

9.80$ -2.1% vs. previous close Closing price · As of: Oct 6, 2026

Statements

Balance Sheet

Korro Bio, Inc. (KRRO) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 163 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet KRRO
Line item Q3 19 Q4 19 Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
171 223 216 205 234 265 242 220 202 185 165 150 136 74 100 109 96 222 198 250 244 226 202 180 162 114 184 163
167 221 210 198 227 225 200 172 150 135 120 113 101 57 82 62 49 173 146 164 153 132 121 103 98 82 120 121
142 200 203 195 224 220 169 135 112 80 50 42 44 37 78 59 46 166 139 91 63 56 64 34 25 22 62 25
165 217 206 195 224 220 195 169 148 131 117 111 99 56 80 60 46 166 139 157 137 126 115 96 93 75 114 115
0.4 0.8 0.2 – – 0.3 – – – 0.1 – – – 0.4 – – – 0.0 – – 10 1.7 1.9 1.1 0.8 1.0 0.0 0.0
227 56 51 43 35 72 64 54 55 55 52 54 54 173 9.0 35 40 52 47 52 64 66 63 65 63 62 64 60
72 53 44 41 33 27 19 9.0 10 11 12 17 20 8.7 8.9 8.1 9.5 19 11 12 14 15 13 17 15 12 15 13
– – 0.4 0.4 0.4 0.4 1.3 1.6 1.7 2.6 5.1 7.7 10 2.9 2.3 1.7 1.0 2.0 1.2 0.5 – 1.3 2.3 2.4 3.1 2.7 2.8 2.9
20 1.2 2.7 2.2 4.1 5.5 5.5 3.9 3.6 2.7 2.2 3.6 4.0 2.6 4.5 3.4 2.8 7.3 4.7 5.7 6.0 4.0 4.2 5.2 2.3 1.7 2.0 3.6
-60 167 165 162 200 192 177 166 147 131 113 96 82 -99 91 74 56 170 151 198 180 160 139 115 99 51 120 103
-63 -69 -74 -80 -85 -95 -116 -133 -159 -180 -203 -225 -244 -102 -121 -139 -158 -183 -203 -224 -245 -267 -290 -316 -334 -384 -403 -422
0.6 0.6 0.6 0.6 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7 5.2 5.4 5.5 5.6 5.7 8.0 8.0 9.0 9.3 8.9 9.4 9.4 9.4 9.4 12 18

Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?